- Home
- JLL vs DVA Comparison
JLL vs DVA Comparison
Compare JLL & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JLL
- DVA
- Stock Information
- Founded
- JLL 1997
- DVA 1994
- Country
- JLL United States
- DVA United States
- Employees
- JLL N/A
- DVA N/A
- Industry
- JLL Real Estate
- DVA Misc Health and Biotechnology Services
- Sector
- JLL Finance
- DVA Health Care
- Exchange
- JLL Nasdaq
- DVA Nasdaq
- Market Cap
- JLL 12.8B
- DVA 10.5B
- IPO Year
- JLL 1997
- DVA 1995
- Fundamental
- Price
- JLL $275.50
- DVA $127.85
- Analyst Decision
- JLL Buy
- DVA Hold
- Analyst Count
- JLL 8
- DVA 3
- Target Price
- JLL $312.43
- DVA $159.33
- AVG Volume (30 Days)
- JLL 379.1K
- DVA 815.1K
- Earning Date
- JLL 08-06-2025
- DVA 08-05-2025
- Dividend Yield
- JLL N/A
- DVA N/A
- EPS Growth
- JLL 47.74
- DVA 8.72
- EPS
- JLL 11.64
- DVA 10.20
- Revenue
- JLL $24,676,200,000.00
- DVA $13,161,328,000.00
- Revenue This Year
- JLL $12.53
- DVA $6.51
- Revenue Next Year
- JLL $8.13
- DVA $3.41
- P/E Ratio
- JLL $23.46
- DVA $12.53
- Revenue Growth
- JLL 13.47
- DVA 5.09
- 52 Week Low
- JLL $194.36
- DVA $126.07
- 52 Week High
- JLL $288.50
- DVA $179.60
- Technical
- Relative Strength Index (RSI)
- JLL 66.19
- DVA 31.46
- Support Level
- JLL $262.33
- DVA $136.79
- Resistance Level
- JLL $282.63
- DVA $141.52
- Average True Range (ATR)
- JLL 6.69
- DVA 4.47
- MACD
- JLL 0.60
- DVA -1.47
- Stochastic Oscillator
- JLL 77.07
- DVA 6.90
About JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.